Notice Number: NOT-CA-18-096

Key Dates
Release Date: July 25, 2018

Issued by
National Cancer Institute (NCI)

Purpose

This Notice is to provide interested investigators with an update on the current status of the National Cancer Institute (NCI) "PREVENT Cancer Preclinical Drug Development Program" that has been the subject of a recent Request for Proposals (RFP, covered by NOT-CA-18-073).

Specifically, this Notice alerts investigators that the NCI has issued, for planning purposes, a Special Notice: "Request for Information for the PREVENT Cancer Preclinical Drug Development Program: Preclinical Services for Biopharmaceutical Product Development and Manufacturing" Solicitation Number HHS-NIH-NCI-RFI-TSB-87006-18 on FedBizOpps.gov. The Special Notice seeks input on the possibility of utilizing a contract mechanism to acquire Preclinical Services for Biopharmaceutical Product Development and Manufacturing in support of the PREVENT Cancer Preclinical Drug Development Program (PREVENT; http://prevention.cancer.gov/major-programs/prevent-cancer-preclinical).

For details about the planned solicitation (including draft Statement of Work and draft Request for Proposals), information sought, and response submission instructions, please see the full FedBizOpps Special Notice posting.

Inquiries

Please direct all inquiries to:

Nicole Belanger
National Cancer Institute (NCI)
Telephone: 301-624-8754
Email: belangern@mail.nih.gov